The FDA and other regulatory bodies responded by reevaluating the safety of COX-2 inhibitors. In 2005, the FDA issued a Public Health Advisory and mandated a boxed warning for all NSAIDs, emphasizing the potential for cardiovascular risk. The FDA's actions were influenced by epidemiological data that highlighted the significance of post-market surveillance in identifying adverse drug reactions that might not be evident during initial clinical trials.
